MRCP2-1279
A 50-year-old male presents with difficulty sleeping, weight loss, and anxiety. He has been taking combined cyclical oestrogen/progesterone hormone replacement therapy for the past two years. On examination, he has a body mass index of 25 kg/m2, a pulse of 100 beats per minute, and a blood pressure of 118/76 mmHg. No goitre is palpable, and eye movements are normal. Weakness of the proximal musculature of the shoulder and hip girdles is noted. Abdominal examination reveals a palpable splenic tip.
Initial investigations reveal the following:
– Serum total thyroxine 260 nmol/L (60-140)
– Plasma TSH <0.1 mU/L (0.4-5.0)
– Serum alkaline phosphatase 190 U/L (45-105)
– Serum gamma glutamyl transferase 28 U/L (4-35)
The patient’s GP prescribes carbimazole 10 mg tds and propranolol 120 mg BD. At the six-week review, the patient appears clinically euthyroid. Repeat investigations show:
– Free thyroxine 190 nmol/L
– Plasma TSH 2.5 mU/L
– Serum alkaline phosphatase 170 U/L
– Serum gamma glutamyl transferase 35 U/L
The dose of carbimazole is decreased to 20 mg daily. After one year, the GP decides to refer the patient to endocrine outpatients. Two weeks before the appointment, the patient had a chest infection treated with erythromycin. His blood test results show:
– Serum thyroxine 85 nmol/L
– Plasma TSH 11.2 mU/L
– Serum alkaline phosphatase 100 U/L
What would be the most appropriate next investigation?